RxDoctor Payments Data

William Taylor, MD

Hematology & Oncology · New Bern, NCNPI 1700094174

Payments from drug & device makers

$1,191in general payments, 2019–2025

Across 63 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$322
  • Pfizer$170
  • Seagen Inc.$99
  • Bristol Myers Squibb$99
  • Merck$76
  • E.r. Squibb & Sons, L.L.C.$76
  • plus $349 from 13 others

What the payments were for

  • Food & beverage$96281%
  • Education$22919%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,191 in reported general payments places this provider in the 30th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$157,017
Medicare patients
546
Services billed
1,799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide59$1,122,405
PomalystPomalidomide30$679,344
Lenalidomide37$562,275
TasignaNilotinib Hcl22$446,195
VenclextaVenetoclax28$431,361
Abiraterone Acetate122$221,673
SprycelDasatinib11$197,059
ImbruvicaIbrutinib12$194,337
EliquisApixaban38$28,838
XareltoRivaroxaban13$8,576
Letrozole201$3,863
Hydroxyurea87$2,708
Anastrozole94$1,669
ValacyclovirValacyclovir Hcl43$1,521
Dexamethasone99$1,237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$99$1,122,40559 claims
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$76$876,40341 claims
AbbVieVenclexta$40$431,36128 claims
PfizerEliquis$170$28,83838 claims
Johnson & JohnsonXarelto$322$8,57613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 358 hematology & oncology providers in North Carolina.

Other hematology & oncology in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →